Novakand Pharma AB (publ) (STO:NOVKAN)

Novakand Pharma AB Income Statement

Financials in millions SEK. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Selling, General & Admin	6.05	6.22	8.09	7.08	4.33
Research & Development	23.56	39.95	57.99	45.61	42.63
Other Operating Expenses	-0.01	-0.01	-	-	-0
Operating Expenses	29.59	46.16	66.08	52.69	46.96
Operating Income	-29.59	-46.16	-66.08	-52.69	-46.96
Interest Expense	-	-	-	-0.12	-0.02
Interest & Investment Income	0.37	1.6	0.28	0.07	-
Currency Exchange Gain (Loss)	-	-	0.45	-0.09	-0.25
Other Non Operating Income (Expenses)	-	-	0.46	0.34	1.54
EBT Excluding Unusual Items	-29.23	-44.57	-64.89	-52.48	-45.69
Asset Writedown	-18	-	-	-	-
Pretax Income	-47.23	-44.57	-64.89	-52.48	-45.69
Net Income	-47.23	-44.57	-64.89	-52.48	-45.69
Net Income to Common	-47.23	-44.57	-64.89	-52.48	-45.69
Shares Outstanding (Basic)	121	115	80	58	56
Shares Outstanding (Diluted)	121	115	80	58	56
Shares Change (YoY)	5.08%	44.85%	36.90%	3.91%	54.18%
EPS (Basic)	-0.39	-0.39	-0.81	-0.90	-0.82
EPS (Diluted)	-0.39	-0.39	-0.81	-0.90	-0.82
Free Cash Flow	-30.29	-58.53	-55.67	-47.56	-44.13
Free Cash Flow Per Share	-0.25	-0.51	-0.70	-0.82	-0.79
EBITDA	-	-43.16	-63.08	-52.33	-46.64
D&A For EBITDA	-	3	3	0.36	0.32
EBIT	-29.59	-46.16	-66.08	-52.69	-46.96

Source: S&P Global Market Intelligence. Standard template. Financial Sources.